These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 21796891)
1. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Isiguzo M; Brunken R; Tchou P; Xu M; Culver DA Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):50-5. PubMed ID: 21796891 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on Sperry BW; Tamarappoo BK; Oldan JD; Javed O; Culver DA; Brunken R; Cerqueira MD; Hachamovitch R JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 2):336-345. PubMed ID: 28823747 [TBL] [Abstract][Full Text] [Related]
3. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis. Dweck MR; Abgral R; Trivieri MG; Robson PM; Karakatsanis N; Mani V; Palmisano A; Miller MA; Lala A; Chang HL; Sanz J; Contreras J; Narula J; Fuster V; Padilla M; Fayad ZA; Kovacic JC JACC Cardiovasc Imaging; 2018 Jan; 11(1):94-107. PubMed ID: 28624396 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of PET in Cardiac Sarcoidosis. Smedema JP; van Kroonenburgh MJ; Snoep G; Bekkers SC; Gorgels AP J Nucl Med; 2004 Nov; 45(11):1975. PubMed ID: 15534072 [No Abstract] [Full Text] [Related]
5. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. Yamagishi H; Shirai N; Takagi M; Yoshiyama M; Akioka K; Takeuchi K; Yoshikawa J J Nucl Med; 2003 Jul; 44(7):1030-6. PubMed ID: 12843216 [TBL] [Abstract][Full Text] [Related]
6. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. Osborne MT; Hulten EA; Singh A; Waller AH; Bittencourt MS; Stewart GC; Hainer J; Murthy VL; Skali H; Dorbala S; Di Carli MF; Blankstein R J Nucl Cardiol; 2014 Feb; 21(1):166-74. PubMed ID: 24307261 [TBL] [Abstract][Full Text] [Related]
7. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. Blankstein R; Osborne M; Naya M; Waller A; Kim CK; Murthy VL; Kazemian P; Kwong RY; Tokuda M; Skali H; Padera R; Hainer J; Stevenson WG; Dorbala S; Di Carli MF J Am Coll Cardiol; 2014 Feb; 63(4):329-36. PubMed ID: 24140661 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. Tahara N; Tahara A; Nitta Y; Kodama N; Mizoguchi M; Kaida H; Baba K; Ishibashi M; Hayabuchi N; Narula J; Imaizumi T JACC Cardiovasc Imaging; 2010 Dec; 3(12):1219-28. PubMed ID: 21163450 [TBL] [Abstract][Full Text] [Related]
9. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis. Shelke AB; Aurangabadkar HU; Bradfield JS; Ali Z; Kumar KS; Narasimhan C Int J Cardiol; 2017 Feb; 228():717-722. PubMed ID: 27886616 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Detection of Myocardial Injury in Active Cardiac Sarcoidosis--Significance of Myocardial Fatty Acid Metabolism and Myocardial Perfusion Mismatch. Momose M; Fukushima K; Kondo C; Serizawa N; Suzuki A; Abe K; Hagiwara N; Sakai S Circ J; 2015; 79(12):2669-76. PubMed ID: 26477356 [TBL] [Abstract][Full Text] [Related]
11. Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment. Santana CA; Faber TL; Soler-Peter M; Sanyal R; Esteves FP; Ornelas M; Folks RD; Verdes L; Santana LF; Candell-Riera J; Garcia EV Nucl Med Commun; 2008 Nov; 29(11):970-81. PubMed ID: 18836375 [TBL] [Abstract][Full Text] [Related]
12. The prognostic role of cardiac positron emission tomography imaging in patients with sarcoidosis: A systematic review. Ahmed AI; Abebe AT; Han Y; Alnabelsi T; Agrawal T; Kassi M; Aljizeeri A; Taylor A; Tleyjeh IM; Al-Mallah MH J Nucl Cardiol; 2021 Aug; 28(4):1545-1552. PubMed ID: 34228337 [TBL] [Abstract][Full Text] [Related]
13. Feasibility of Osiecki S; Sterliński M; Marciniak-Emmons M; Dziuk M Int J Cardiovasc Imaging; 2021 Mar; 37(3):1097-1104. PubMed ID: 33063243 [TBL] [Abstract][Full Text] [Related]
14. Fasting FDG PET compared to MPI SPECT in cardiac sarcoidosis. Brancato SC; Arrighi JA J Nucl Cardiol; 2011 Apr; 18(2):371-4. PubMed ID: 21318450 [No Abstract] [Full Text] [Related]
15. Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis. Lu Y; Grant C; Xie K; Sweiss NJ Clin Nucl Med; 2017 Feb; 42(2):88-94. PubMed ID: 27922863 [TBL] [Abstract][Full Text] [Related]
16. Imaging Cardiac Sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET: A Prospective Pilot Study. Martineau P; Pelletier-Galarneau M; Juneau D; Leung E; Nery PB; de Kemp R; Beanlands R; Birnie D JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 1):2280-2281. PubMed ID: 31422126 [No Abstract] [Full Text] [Related]
17. Advances in radionuclide imaging of cardiac sarcoidosis. Kouranos V; Wells AU; Sharma R; Underwood SR; Wechalekar K Br Med Bull; 2015 Sep; 115(1):151-63. PubMed ID: 26311504 [TBL] [Abstract][Full Text] [Related]
18. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis. Skali H; Schulman AR; Dorbala S Curr Cardiol Rep; 2013 May; 15(5):352. PubMed ID: 23504346 [TBL] [Abstract][Full Text] [Related]
19. FDG-PET in possible cardiac sarcoidosis: Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events. Tuominen H; Haarala A; Tikkakoski A; Kähönen M; Nikus K; Sipilä K J Nucl Cardiol; 2021 Feb; 28(1):199-205. PubMed ID: 30815833 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity. Ito K; Morooka M; Okazaki O; Minaminoto R; Kubota K; Hiroe M Clin Nucl Med; 2013 Feb; 38(2):128-30. PubMed ID: 23334129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]